TrialCancer2014

Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia.

Aristoteles Giagounidis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.